Halyard Health Upgrades ON-Q* TRAC Patient Engagement Platform for Physicians and Hospitals
Deeper Patient Insights and Better Threshold Notifications
Enable Faster Intervention and Treatment Modifications

IRVINE, Calif., March 9, 2018 /PRNewswire/ -- AAOS 2018 — Halyard Health (NYSE: HYH), a medical technology company focused on eliminating pain, speeding recovery and preventing infection, today announced the availability of ON-Q* TRAC 3.0, the latest version of its online patient engagement platform allowing physicians to monitor, measure and track patients' post-operative satisfaction and pain to improve the overall patient experience.1 ON-Q TRAC 3.0, along with Halyard's full suite of pain management products, is currently on display at Halyard booth #6233 at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting.

Halyard Health logo (PRNewsFoto/Halyard Health)

The new ON-Q TRAC 3.0 platform allows physicians to set pre-configurable threshold notifications, allowing for direct follow-up on specific care metrics that exceed providers' acceptable recovery values including pain, sleep, functional activity and more. Additionally, ON-Q TRAC 3.0 includes capabilities for real-time alerts via text or email that can help physicians to better track key outcome data and patient feedback and provide opportunities for appropriate intervention to potentially reduce readmissions and lower opioid consumption. Studies show that increased physician to patient connectivity enhances patient satisfaction scores, helps improve outcomes and can boost reputation and referrals.1,2,3,4,5,6

With ON-Q TRAC 3.0, physicians are also able to benchmark and compare their patients' progress against other patients and physician practices around the country in the ON-Q TRAC database. This enhanced analysis provides physicians with deeper insights into how their patients' progress compares to other facilities so they can quickly and efficiently modify protocols and treatment plans for improved outcomes.

Additional ON-Q TRAC 3.0 analytical upgrades include:

  • New chart drill-down functionality allows providers to easily analyze outcomes at the individual patient case level.
  • Resource center featuring Halyard patient education materials, which can be delivered directly to patients via a web-browser or smartphone.
  • Ability to compare outcomes between pain management modalities to evaluate the effect of different treatments to ensure optimal patient recovery.

"Between 1999 and 2013, the prescription opioid overdose rate for adults aged 55 to 64 increased more than seven times," said Roger Massengale, general manager, acute pain, Halyard Health. "It's clear that the healthcare community needs to find a better way of fostering open communication between patients and their providers regarding post-surgical pain management. By combining real-time alerts and powerful analytics, ON-Q TRAC 3.0 is designed to help Halyard's customers better manage their patients' pain and make more informed decisions regarding need to prescribe opioids post-surgery."

To learn more about ON-Q TRAC 3.0, which includes Spanish language interface, please visit http://www.halyardhealth.com/ON-QTRAC.

ON-Q TRAC is not a medical device.


ON-Q TRAC helps engage patients, enhance connectivity and improve collaboration between patients and physicians. Patients are enrolled in the platform before surgery and are invited to provide information at various time intervals – from pre-operative through 90-days post-surgery – via a user-friendly survey that can be completed on either a desktop or mobile device. Based on this patient input, physicians are able to track patients' pain levels and satisfaction with their treatment and care.

About Halyard Health

Halyard Health (NYSE: HYH) is a medical technology company focused on eliminating pain, speeding recovery and preventing infection for healthcare providers and their patients. Headquartered in Alpharetta, Georgia, Halyard is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Halyard's Medical Device business develops, manufactures and markets clinically superior solutions that improve medical outcomes and business performance in more than 90 countries. For more information, visit www.halyardhealth.com.

*Registered Trademarks or Trademarks of Halyard Health, Inc. or its affiliates. 

1 Heller L, Kowalski AM, Wei C, Butler CE. Prospective, randomized, double-blind trial of local anesthetic infusion and intravenous narcotic patient-controlled anesthesia pump for pain management after free TRAM flap breast reconstruction. Plast Reconstr Surg. 2008;122(4):1010-1018.
2 Liu SS, Richman JM, Thirlby RC, Wu CL. Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. J Am Coll Surg. 2006;203(6):914-932.
3 Beaussier M, El'Ayoubi H, Schiffer E, et al. Continuous preperitoneal infusion of ropivacaine provides effective analgesia and accelerates recovery after colorectal surgery. Anesthesiology. 2007;107(3):461-468.
4 Bingham AE, Fu R, Horn JL, Abrahams MS. Continuous peripheral nerve block compared with single-injection peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2012;37(6):583-594.
5 Kean J, Wigderowitz CA, Coventry DM. Continuous interscalene infusion and single injection using levobupivacaine for analgesia after surgery of the shoulder: a double-blind, randomized controlled trial. J Bone Joint Surg [Br]. 2006;88-B:1173-1177.
6 Husain A, Lee GC. Establishing realistic patient expectations following total knee arthroplasty. J Am Acad Orthop Surg. 2015;23(12):707-713.

SOURCE Halyard Health

For further information: Maggie Fairchild, MSLGROUP, (781) 684-0770, ON-Q@mslgroup.com